Ligand (LGND) Breakout! Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout!

LGND 188.41

-2.4%

3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: growthvalue who wrote (24972)	8/28/1998 9:02:00 AM
From: Henry Niman	of 32384

I was think in terms of an overall concern by the end user. It raises concerns about combining medications. Because of countless combinations, most drugs are approved as monotherapy, but frequently they are combined, based on individual trials. The potential problems could therefore generate additional concerns. I expect future treatments to increasing rely on combination approaches and I'm not sure how much real impact the potential problems of combining the fen/phe drugs really poses. The initial data that I saw seemed to point very strongly to Redux and Pondimin since patients taking Redux alone developed heart valve problems. The data being presented seems to raise concerns that has not been demonstrated in the patient population, but the theoretical possibilities may raise concerns that are not real.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next